<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01088841</url>
  </required_header>
  <id_info>
    <org_study_id>EKBB 69/04.01</org_study_id>
    <nct_id>NCT01088841</nct_id>
  </id_info>
  <brief_title>Sweet Taste Receptors and the Secretion of Glucagon-like Peptide-1 and Peptide YY</brief_title>
  <official_title>The Functional Significance of Gut-expressed Taste Receptors in the Secretion of Glucagon-like Peptide-1 and Peptide YY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the functional significance of sweet taste
      receptors in the secretion of GI satiety peptides by using a specific sweet taste receptor
      antagonist to block sweet taste perception in the gut.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is strong evidence that taste signaling mechanisms identified in the oral epithelium
      also operate in the gut. It is suggested that open-type enteroendocrine cells directly sense
      nutrient via alpha-gustducin coupled taste receptors to modulate the secretion of glucagon
      like peptide-1 (GLP-1) and peptide YY (PYY). Several nutrient responsive G-protein coupled
      receptors have been identified in the human gut, including the sweet taste responsive
      T1R2/T1R3 heterodimer, the amino acid/umami responsive T1R1/T1R3 as well as GPR120 for
      unsaturated long-chain free fatty acids.The functional significance of sweet taste receptors
      in glucose stimulated secretion of GLP-1 and PYY will be determined by intragastric infusion
      of 75 g glucose with different concentrations of lactisole (150 ppm, 300 ppm and 450 ppm)in a
      double blind, 4-way crossover trial including 16 healthy subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastrointestinal peptide secretion</measure>
    <time_frame>2 hours blood sampling</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Appetite and General Nutritional Disorders</condition>
  <condition>Hormone Replacement</condition>
  <arm_group>
    <arm_group_label>75 g glucose + 150 ppm lactisole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>75 g glucose + 300 ppm lactisole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>75 g glucose + 450 ppm lactisole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>75 g glucose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>lactisole</intervention_name>
    <description>lactisole (flavoring agent/sweet taste antagonist) dissolved with 75 g glucose in 300 mL tap water; administered via intragastric tube</description>
    <arm_group_label>75 g glucose + 150 ppm lactisole</arm_group_label>
    <arm_group_label>75 g glucose + 300 ppm lactisole</arm_group_label>
    <arm_group_label>75 g glucose + 450 ppm lactisole</arm_group_label>
    <arm_group_label>75 g glucose</arm_group_label>
    <other_name>Glucose</other_name>
    <other_name>water</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects

          -  BMI of 19.0-24.5

          -  Age 18-40

          -  stable body weight for at least 3 month

        Exclusion Criteria:

          -  smoking

          -  substance abuse

          -  regular intake of medication

          -  medical or psychiatric illness

          -  gastrointestinal disorders or food allergies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Beglinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research Center, University Hospital Basel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Basel, Clinical Research Center</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2010</study_first_submitted>
  <study_first_submitted_qc>March 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2010</study_first_posted>
  <last_update_submitted>February 22, 2011</last_update_submitted>
  <last_update_submitted_qc>February 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Beglinger Christoph, Prof. Dr. med.</name_title>
    <organization>Department of Gastroenterology, University Hospital Basel, Basel, Switzerland</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nutrition Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

